We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medpace (MEDP) Dips More Than Broader Market: What You Should Know
Read MoreHide Full Article
Medpace (MEDP - Free Report) ended the recent trading session at $487.95, demonstrating a -1.88% change from the preceding day's closing price. The stock fell short of the S&P 500, which registered a loss of 0.5% for the day. Meanwhile, the Dow experienced a drop of 0.38%, and the technology-dominated Nasdaq saw a decrease of 0.5%.
Shares of the provider of outsourced clinical development services have appreciated by 5.04% over the course of the past month, outperforming the Medical sector's loss of 0.7%, and the S&P 500's gain of 2.74%.
Market participants will be closely following the financial results of Medpace in its upcoming release. The company plans to announce its earnings on October 22, 2025. It is anticipated that the company will report an EPS of $3.49, marking a 15.95% rise compared to the same quarter of the previous year. Alongside, our most recent consensus estimate is anticipating revenue of $640.76 million, indicating a 20.14% upward movement from the same quarter last year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $13.99 per share and a revenue of $2.46 billion, signifying shifts of +10.77% and +16.83%, respectively, from the last year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Medpace. These revisions help to show the ever-changing nature of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. Currently, Medpace is carrying a Zacks Rank of #3 (Hold).
With respect to valuation, Medpace is currently being traded at a Forward P/E ratio of 35.55. This valuation marks a premium compared to its industry average Forward P/E of 16.94.
Investors should also note that MEDP has a PEG ratio of 3.13 right now. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. MEDP's industry had an average PEG ratio of 1.68 as of yesterday's close.
The Medical Services industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 98, which puts it in the top 40% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Medpace (MEDP) Dips More Than Broader Market: What You Should Know
Medpace (MEDP - Free Report) ended the recent trading session at $487.95, demonstrating a -1.88% change from the preceding day's closing price. The stock fell short of the S&P 500, which registered a loss of 0.5% for the day. Meanwhile, the Dow experienced a drop of 0.38%, and the technology-dominated Nasdaq saw a decrease of 0.5%.
Shares of the provider of outsourced clinical development services have appreciated by 5.04% over the course of the past month, outperforming the Medical sector's loss of 0.7%, and the S&P 500's gain of 2.74%.
Market participants will be closely following the financial results of Medpace in its upcoming release. The company plans to announce its earnings on October 22, 2025. It is anticipated that the company will report an EPS of $3.49, marking a 15.95% rise compared to the same quarter of the previous year. Alongside, our most recent consensus estimate is anticipating revenue of $640.76 million, indicating a 20.14% upward movement from the same quarter last year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $13.99 per share and a revenue of $2.46 billion, signifying shifts of +10.77% and +16.83%, respectively, from the last year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Medpace. These revisions help to show the ever-changing nature of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. Currently, Medpace is carrying a Zacks Rank of #3 (Hold).
With respect to valuation, Medpace is currently being traded at a Forward P/E ratio of 35.55. This valuation marks a premium compared to its industry average Forward P/E of 16.94.
Investors should also note that MEDP has a PEG ratio of 3.13 right now. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. MEDP's industry had an average PEG ratio of 1.68 as of yesterday's close.
The Medical Services industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 98, which puts it in the top 40% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.